Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C23H29N |
Molar mass | 319.492 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Igmesine (JO-1,784) is a sigma receptor agonist ( IC50 = 39 nM (rat brain)). [1] [2] It has neuroprotective and antidepressant-like effects in animal studies, [3] [4] as well as nootropic effects in models of age-related cognitive decline. [5] In two phase II clinical trials, igmesine was found to be effective in the treatment of depression and was as active as the comparator fluoxetine. [2] However, in a large phase III clinical trial, igmesine failed to show significant effectiveness for depression. [6] The drug has not been developed further. [7]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C23H29N |
Molar mass | 319.492 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Igmesine (JO-1,784) is a sigma receptor agonist ( IC50 = 39 nM (rat brain)). [1] [2] It has neuroprotective and antidepressant-like effects in animal studies, [3] [4] as well as nootropic effects in models of age-related cognitive decline. [5] In two phase II clinical trials, igmesine was found to be effective in the treatment of depression and was as active as the comparator fluoxetine. [2] However, in a large phase III clinical trial, igmesine failed to show significant effectiveness for depression. [6] The drug has not been developed further. [7]